Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
| Autor: | Davids, Matthew S *, Lampson, Benjamin L, Tyekucheva, Svitlana, Wang, Zixu, Lowney, Jessica C, Pazienza, Samantha, Montegaard, Josie, Patterson, Victoria, Weinstock, Matthew, Crombie, Jennifer L, Ng, Samuel Y, Kim, Austin I, Jacobson, Caron A, LaCasce, Ann S, Armand, Philippe, Arnason, Jon E, Fisher, David C, Brown, Jennifer R |
|---|---|
| Zdroj: | In The Lancet Oncology October 2021 22(10):1391-1402 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|